If Roche is successful in securing FDA approval, use of pertuzumab together with trastuzumab (also developed by Genentech's parent company, Roche) could help the drug maker hold on to some of its oncology market dominance in the face of growing competition from anticancer biosimilars.
Genentech, a member of the Roche Group, has announced that it has been granted FDA priority review for its supplemental biologics license application (sBLA) for pertuzumab (Perjeta), together with trastuzumab (Herceptin) and chemotherapy, for adjuvant treatment of HER2-positive early breast cancer (EBC). The FDA is expected to issue a regulatory decision by January 28, 2018.
The sBLA relies on data from the phase 3 APHINITY study. The international, randomized, double-blind, placebo-controlled, 2-arm study evaluated the efficacy and safety of trastuzumab and chemotherapy combined with either pertuzumab or placebo, as adjuvant treatment in 4805 patients who had operable HER2-positive EBC. The study’s primary endpoint was invasive disease-free survival (iDFS), which the study defined as the time that a patient lives without the return of invasive breast cancer at any site and without death from any cause after adjuvant treatment.
The rate of iDFS at 3 years was 94.1% in the pertuzumab, trastuzumab, and chemotherapy arm, and 93.2% in the trastuzumab, chemotherapy, and placebo arm. Estimated iDFS at 4 years, based upon data available to date, was 92.3% and 90.6% in the 2 arms, respectively.
The fact that the FDA has granted a priority review of the drug—a review designation available only to medicines that the agency has determined to have the potential to provide significant improvements in treatment, prevention, or diagnosis of a disease—suggests that the agency may see the APHINITY study’s results as more impressive than investors did. When results of the trial were announced in June, Roche’s stock sank by 5.2% on concerns that the high cost of pertuzumab therapy relative to the improvements that it offered would keep the drug from being widely used in low-risk patients.
An analysis published in the Journal of Clinical Oncology, which assessed cost effectiveness of pertuzumab plus trastuzumab in the earlier CLEOPATRA study (a study that assessed pertuzumab and trastuzumab in metastatic breast cancer), concluded that use of the combination was unlikely to be cost effective, at least in treating metastatic breast cancer, in the United Sates.
If Roche is successful in securing FDA approval, use of pertuzumab together with trastuzumab (also developed by Roche) could help the drug maker hold on to some of its oncology market dominance in the face of growing competition from anticancer biosimilars. Additionally, some analysts have said that the fact that pertuzumab would extend the duration of a patient’s treatment will contribute to higher sales overall sales for Roche.
What Stands in the Way of Biosimilar Use Across MENA Countries?
May 21st 2025Despite the clear promise of cost savings and expanded access, the path to integrating generics and biosimilars across the Middle East and North Africa (MENA) region is tangled in a web of distrust, inconsistent policies, and deep-rooted cultural preferences for branded drugs.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
The Trump Administration’s Drug Price Actions and Why US Prices Are Already Sky-High
May 17th 2025While the Trump administration’s latest executive order touts sweeping drug price cuts through international benchmarking, the broader pharmaceutical pricing crisis in the US reveals a far more complex web of development costs, profit incentives, and absent price controls—raising the question of whether any single policy, including potential drug tariffs, can truly untangle it.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.